Interpreting Clonal Hematopoiesis Following [ <sup>177</sup> Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal
TO THE EDITOR: We read with interest the study by Munzur et al. evaluating clonal hematopoiesis (CH) after [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer ([1][1]). We commend the authors for addressing a timely question as [177Lu]Lu-PSMA-617 is increasingly
Authors
- Ashwani Sood (ORCID: https://orcid.org/0000-0001-7228-0361)
- Piyush Aggarwal
- Swayamjeet Satapathy
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2026-03-26
- DOI
- https://doi.org/10.2967/jnumed.126.272410
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00